Clinical Trial Update: Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab with or without vismodegib for metastatic or unresectable basal cell carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vismodegib (Vismodegib)

Snippet

Sponsor: Anne Chang | Conditions: Skin Basal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-08